Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084058 · ClinicalTrials.gov registry record · Phase 1
Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00084058 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 26 participants.
The verdict
NCT00084058, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effect of increased doses of lopinavir/ritonavir (LPV/r) and saquinavir (SQV) in HIV infected children who are failing their current antiretroviral regimen
Interventions
- DRUG Saquinavir
- DRUG Lopinavir/ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084058
The ClinicalTrials.gov registry entry for NCT00084058 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saquinavir is the first listed.
NCT00084058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084058 about?
NCT00084058 is a clinical study titled "Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV". The purpose of this study is to determine the effect of increased doses of lopinavir/ritonavir (LPV/r) and saquinavir (SQV) in HIV infected children who are failing their current antiretroviral regimen
What is the current status of trial NCT00084058?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00084058?
The interventions under investigation include: Saquinavir (DRUG), Lopinavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT00084058?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.